We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT.

Original publication

DOI

10.1097/INF.0b013e31813429fa

Type

Journal

Pediatr Infect Dis J

Publication Date

11/2007

Volume

26

Pages

1057 - 1059

Keywords

Antibodies, Bacterial, Diphtheria-Tetanus-Pertussis Vaccine, Haemophilus Infections, Haemophilus Vaccines, Haemophilus influenzae type b, Humans, Immunization, Immunization Schedule, Infant, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup C, Poliovirus Vaccine, Inactivated, Tetanus Toxoid, Vaccines, Combined, Vaccines, Conjugate